Drug for treating solid malignant tumors and preparation method

Abstract

The invention belongs to the technical field of a chemotherapeutic drug wrapped by a nano-carrier, and discloses a drug for treating solid malignant tumors and a preparation method. The drug for treating solid malignant tumors is the chemotherapeutic drug wrapped by the nano-carrier. The drug wrapped by the nano-carrier for wrapping the chemotherapeutic drug consists of a shell of the nano-carrier of a polylactic acid-glycollic acid copolymer and dipalmitoyl phosphatidylcholine. hyaluronic acid used for targeting a tumor cell factor CD44, a 1-butyl-3-methylimidazole-L-lactic acid as a thermal sensitizer, and Ptx paclitaxel; the molar ratio of the polylactic acid-glycollic acid copolymer to the dipalmitoyl phosphatidylcholine is (1: 3)-(1: 5); and 1 to 5 * 10 <-4> mmol / mL of the hyaluronic acid, 2 to 10 *10 <-5> mmol / mL of the 1-butyl-3-methylimidazole-L-lactic acid, and 1 to 5 mg / mL of the Ptx. The microenvironment of tumors is effectively improved, interstitial fluid pressure of tumor tissue is reduced, and the drug resistance of the tumor tissue is reduced.

Description

technical field [0001] The invention belongs to the technical field of chemotherapy drugs encapsulated by nanocarriers, and in particular relates to a drug for treating solid malignant tumors and a preparation method thereof. Background technique [0002] Currently, chemotherapy is less effective for solid tumors, such as breast cancer. Breast cancer is the most common cancer among women worldwide and one of the leading causes of cancer-related death. Despite methods for early detection and intervention, metastatic breast cancer remains largely incurable, especially triple-negative breast cancer (TNBC). TNBC is an aggressive subtype of breast cancer, accounting for 10-20% of all breast cancer cases. Due to the lack of specific targets and the high probability of metastasis, currently available treatment options are very limited. Metastatic breast cancer is characterized by a unique tumor microenvironment (TME) that is distinct from other subtypes. Components of the TME i...

AI Technical Summary

Problems solved by technology

[0006] (1) Currently available treatment options are very limited due to lack of specific targets and high probability of metastasis

[0007] (2) For the method of hyperthermia combined with nanoparticles and chemotherapeutic drugs to treat cancer, the efficacy in the treatment of solid malignant tumors has not been clinically proven

[0008] (3) Most of the existing Phase II and Phase III clinical trials have failed to prove that combined nano-drug therapy is superior to chemotherapy or hyperthermia alone, so the preclinical research and clinical transformation of chemotherapeutic drugs encapsulated by thermosensitive nanocarriers still face huge challenges. needs and challenges

[0009] The difficulties in solving the above problems and defects are as follows: (1) It is difficult for the chemotherapeutic drugs wrapped in the carrier to reach the local tumor tissue (<1%), and the nanometer cannot produce the EPR effect (Enhanced Permeation and Retention effect) in solid tumors; (2) Solid malignant Tumor tumor microenvironment (high interstitial fluid pressure, decreased blood perfusion, immunosuppression); (3) natural immune system clearance response to nanomedicine (opsonization, complement response, immune cell phagocytosis, etc.)

Images